Keywords: عوارض جانبی ناشی از ایمنی; Immune checkpoint inhibitors; Immune-related adverse events; Drug induced liver injury; Autoimmune hepatitis;
مقالات ISI عوارض جانبی ناشی از ایمنی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: عوارض جانبی ناشی از ایمنی; Immune checkpoint inhibitors; Immune-related adverse events; Elderly cancer patients;
Keywords: عوارض جانبی ناشی از ایمنی; Cancer; Immunotherapy; Checkpoint modulators; Cancer vaccines; Adoptive immunotherapy; CAR-T; Immune-related adverse events; Oncologic emergency;
Keywords: عوارض جانبی ناشی از ایمنی; PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: عوارض جانبی ناشی از ایمنی; Immunotherapy; Immune-related adverse events; Immune checkpoints inhibitors;
Keywords: عوارض جانبی ناشی از ایمنی; Immunotherapy; toxicity; checkpoint inhibition; immune-related adverse events;
Keywords: عوارض جانبی ناشی از ایمنی; Immune-related adverse events; Autoimmune diseases; PD-1 antibodies; CTLA-4 antibodies; IRIS; ASIA syndrome; Therapy;
Keywords: عوارض جانبی ناشی از ایمنی; Checkpoint inhibitors; Immune-related adverse events; Sarcoidosis-like reactions;
Keywords: عوارض جانبی ناشی از ایمنی; ICIs; immune checkpoint inhibitors; irAEs; immune-related adverse events; NK-1R; neurokinin-1 receptor; NSCLC; non-small-cell lung cancer; SJS; Stevens-Johnson syndrome; immune checkpoint inhibitors; immune-related adverse events; nivolumab; Stevens-Johns
Keywords: عوارض جانبی ناشی از ایمنی; Melanoma; Checkpoint inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; Immune-related adverse events;
Keywords: عوارض جانبی ناشی از ایمنی; NSCLC; non-small cell lung cancer; irAE; immune-related adverse events; IIP; idiopathic interstitial pneumonia; UIP; usual interstitial pneumonia; PD-1; programmed cell death 1; ILD; interstitial lung disease; AE-IIP; acute exacerbation of idiopathic inte
Keywords: عوارض جانبی ناشی از ایمنی; Immune-related adverse events; Hypophysitis; Thyroiditis; Ipilimumab; Nivolumab; Melanoma;
Keywords: عوارض جانبی ناشی از ایمنی; Immune checkpoint inhibitors; Therapeutic monoclonal antibodies; CTLA4; PD-1 - PDL-1 axis; Immune-related adverse events;
Keywords: عوارض جانبی ناشی از ایمنی; Checkpoint inhibitors; Immune-related adverse events; Meta-analysis; Systematic review; Clinical trials;
Keywords: عوارض جانبی ناشی از ایمنی; Nivolumab; Non-small-cell-lung cancer; Programmed death 1; Immune thrombocytopenia; Immune-related adverse events;
Keywords: عوارض جانبی ناشی از ایمنی; Cancer; Hypophysitis; Immune checkpoint inhibition; Immune-related adverse events; Thyroiditis;
Keywords: عوارض جانبی ناشی از ایمنی; Immune-checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Nivolumab; Pembrolizumab; Melanoma; Lung cancer; Renal cancer
Keywords: عوارض جانبی ناشی از ایمنی; Immune-related adverse events; Immune checkpoint blockade; Cytotoxic T-lymphocyte-associated antigen 4; Anti-PD-1 antibody; Tumour neoantigen;
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma
Keywords: عوارض جانبی ناشی از ایمنی; Metastatic melanoma; Targeted Therapy; Immune-related adverse events; BRAF inhibitor melanoma;
Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report
Keywords: عوارض جانبی ناشی از ایمنی; Goodpasture's disease; Immune-related adverse events; Nivolumab; Programmed cell death protein 1;
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Keywords: عوارض جانبی ناشی از ایمنی; Binimetinib (PubChem CID: 10288191); Cobimetinib (PubChem CID: 16222096); Dabrafenib (PubChem CID: 44462760); Encorafenib (PubChem CID: 50922675); Trametinib (PubChem CID: 11707110); Vemurafenib (PubChem CID: 42611257); ATC; adoptively transferred T cells
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions
Keywords: عوارض جانبی ناشی از ایمنی; Immune-checkpoint inhibitors; Non-small cell lung cancer; Immune-related adverse events; Brain metastases; Steroids;
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT
Keywords: عوارض جانبی ناشی از ایمنی; FDG; PET-CT; melanoma; ipilimumab; immune-related adverse events;
Complications rhumatologiques de l'immunothérapie anticancéreuse
Keywords: عوارض جانبی ناشی از ایمنی; Immunothérapie; Cancer; Inhibiteurs checkpoint immunitaire; Immune-Related Adverse Events; Arthralgies; Myalgies; Polyarthrite; Pseudopolyarthrite rhizomélique; Myosites;
PD-1 checkpoint inhibition: Toxicities and management
Keywords: عوارض جانبی ناشی از ایمنی; Immune-related adverse events; PD-1 inhibitor; PD-L1 inhibitor; Treatment; Management; Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab;
ReviewMyasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
Keywords: عوارض جانبی ناشی از ایمنی; Immune checkpoint inhibitors; Myasthenia gravis; Immune-related adverse events; Pembrolizumab; Nivolumab; Ipilimumab; PD-1; CTLA-4; Autoimmunity;
Original ResearchProgrammed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Keywords: عوارض جانبی ناشی از ایمنی; Metastatic melanoma; Nivolumab; Pembrolizumab; PD-1 inhibitor; Autoimmunity; Ipilimumab; Immune-related adverse events;
Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Keywords: عوارض جانبی ناشی از ایمنی; Pneumonitis; Anti-PD-1; Anti-CTLA-4; Checkpoint inhibitors; Immunotherapy; Immune-related adverse events;
Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology
Keywords: عوارض جانبی ناشی از ایمنی; Arthritis; Sicca syndrome; Immune checkpoint inhibitors; Malignancy; Immune-related adverse events;
Auto-immunité et gestion des toxicités des traitements par anti-check point inhibiteurs
Keywords: عوارض جانبی ناشی از ایمنی; Immunothérapie; Checkpoint Inhibiteurs; Effets indésirables liés à une immunothérapie; Auto-immunité; Immunotherapy; Immune checkpoint inhibitors; Immune-related Adverse events; autoimmunity;
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Keywords: عوارض جانبی ناشی از ایمنی; Immunotherapy; PD-1; Nivolumab; Pembrolizumab; Adverse drug reaction; Immune-related adverse events;
The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
Keywords: عوارض جانبی ناشی از ایمنی; adverse event; cancer; drug reaction; ipilimumab; melanoma; rash; AE; adverse events; ASCO; American Society of Clinical Oncology; CI; confidence interval; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; FDA; Food and Drug Administration; IL; inter
Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)
Keywords: عوارض جانبی ناشی از ایمنی; Breakdown; Efficacy; Improve; Ipilimumab; Tolerance; Safety; Yervoy; allo-HSCT; allogeneic hematopoietic stem cell transplantation; APC; antigen-presenting cell; CLL; chronic lymphocytic leukemia; CTLA-4; cytotoxic T lymphocyte-associated antigen-4; gp100